---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-012714"
form_type: "8-K"
ticker: "TOI"
cik: "0001799191"
company_name: "Oncology Institute, Inc."
filed_at: "2022-05-05T23:59:59+00:00"
generated_at: "2026-06-25T23:55:54.577578+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CFO Scott Dalgleish departs April 29; enters consulting pact through May 31, 2022

## Summary
- CFO Scott Dalgleish's last employment date was April 29, 2022; consulting agreement effective April 30 to May 31, 2022.
- Consulting agreement allows continued vesting of up to 15,183 stock options; exercise period extended to Dec 31, 2022.
- Separation and consulting terms described as ordinary course transition; no replacement named.

## SEC filing metadata
- accession: 0001628280-22-012714
- form_type: 8-K
- ticker: TOI
- cik: 0001799191
- company_name: Oncology Institute, Inc.
- filed_at: 2022-05-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799191/000162828022012714/0001628280-22-012714-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799191/000162828022012714/toi-20220429.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-012714
- JSON: https://secwatch.observer/filing/0001628280-22-012714.json
- Plain text: https://secwatch.observer/filing/0001628280-22-012714.txt

## Key facts
- Executive change
  Scott Dalgleish departed as Chief Financial Officer at Oncology Institute, Inc..
  - Action: departed
  - Role: Chief Financial Officer
  source text: Mr. Dalgleish’s last date of employment with the Company was April 29, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1799191/000162828022012714/0001628280-22-012714-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.